Lyell Immunopharma, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Lyell Immunopharma, Inc. (LYEL) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 239.38 thousand shares for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-11-12
- Lyell Immunopharma, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 239.38K shares, a 1623.05% increase year-over-year.
- Lyell Immunopharma, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 42.71K shares, a 246.89% increase year-over-year.
- Lyell Immunopharma, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 13.89K shares.
- Lyell Immunopharma, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 12.31K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month |
|---|---|---|---|
| 2021-09-30 | 239.38K shares 10-Q · filed 2021-11-12 | 141.05K shares derived: average of 2 quarters · filed 2021-11-12 | 100.60K shares 10-Q · filed 2021-11-12 |
| 2021-06-30 | 42.71K shares 10-Q · filed 2021-08-12 | 30.06K shares 10-Q · filed 2021-08-12 | |
| 2020-09-30 | 13.89K shares 10-Q · filed 2021-11-12 | 13.10K shares derived: average of 2 quarters · filed 2021-11-12 | 12.63K shares 10-Q · filed 2021-11-12 |
| 2020-06-30 | 12.31K shares 10-Q · filed 2021-08-12 | 11.98K shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |